In the Alex study, the efficacy of Crizotinib in patients with ALK positive NSCLC who received previous radiotherapy was better than that of untreated patients, and the ORR of the central nervous system was 71.4% and 40.0%, respectively. Here, ALK is linked to non-small cell lung carcinoma.